NCT06705530 is a Phase 1, PHASE2 clinical trial of Hem101 in Non-Hodgkin Lymphoma, B-cell, sponsored by National Research Center for Hematology, Russia.

Who is sponsoring NCT06705530?

NCT06705530 is sponsored by National Research Center for Hematology, Russia.

What drugs are being tested in NCT06705530?

Interventions in NCT06705530: Hem101.

What condition does NCT06705530 study?

NCT06705530 studies Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL.

Is NCT06705530 still recruiting?

NCT06705530 is currently completed. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT06705530

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders

Completed Phase 1, PHASE2 Last updated 9 February 2026

What this trial tests

Phase 1, PHASE2 trial testing Hem101 in Non-Hodgkin Lymphoma, B-cell in 58 participants. Completed in 17 November 2025.

Timeline

26 November 2024

Primary endpoint
17 October 2025

17 November 2025

Quick facts

Lead sponsor	National Research Center for Hematology, Russia
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	26 November 2024
Primary completion	17 October 2025
Estimated completion	17 November 2025
Sites	1 location across Russia

Drugs / interventions tested

Hem101 — full drug profile →

Conditions studied

Non-Hodgkin Lymphoma, B-cell — all drugs for Non-Hodgkin Lymphoma, B-cell →
Acute Lymphoblastic Leukemia ALL — all drugs for Acute Lymphoblastic Leukemia ALL →

Sponsor

National Research Center for Hematology, Russia — full company profile →

Who can join

Adults 18 to 70, any sex, with Non-Hodgkin Lymphoma, B-cell or Acute Lymphoblastic Leukemia ALL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is testing a new type of treatment called anti-CD19 CAR-T cell therapy for adults with certain blood cancers that have returned or did not respond to previous treatments. CAR-T cells are a type of immune cell that is specially designed in a lab to target and destroy cancer cells with a marker called CD19. The main goals of this study are to find out if this treatment is safe, how well patients tolerate it, and how effective it is at controlling cancer. The study will include 60 adults, ages 18-70, who meet specific criteria for participation. Patients will first receive a short course of chemotherapy to prepare their bodies for the CAR-T cells. The CAR-T cells will then be given in two doses through an IV. Patients will be monitored closely in the hospital for about a month to check for any side effects and see how their cancer responds. The researchers will also follow up with patients over time to learn more about how long the CAR-T cells stay active, how well they fight cancer, and the overall health of the patients after treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Non-Hodgkin Lymphoma, B-cell

Currently open trials in the same condition.

NCT06213636 — Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). · Phase 1, PHASE2 · recruiting
NCT06446128 — A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) · EARLY_PHASE1 · recruiting

Other National Research Center for Hematology, Russia trials

Trials by the same sponsor.

NCT06721598 — An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproli · not yet recruiting
NCT06237192 — MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients · NA · recruiting
NCT06188676 — Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunother · Phase 3 · recruiting
NCT05158608 — Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis · Phase 3 · unknown
NCT05165719 — Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06705530 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Research Center for Hematology, Russia
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06705530.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing